Abstract
719P Tyrosine kinase inhibitors and/or immune checkpoint inhibitors is required for improving efficacy of transarterial chemoembolization for hepatocellular carcinoma: A large-scale multicenter real-world study of 582 patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have